Investigational Therapies For Graft-versus-host Disease
There are a large number of clinical trials either ongoing or recently completed in the investigation of graft-versus-host disease treatment and prevention.
On May 17, 2012, Osiris Therapeutics announced that Canadian health regulators approved Prochymal, its drug for acute graft-versus host disease in children who have failed to respond to steroid treatment. Prochymal is the first stem cell drug to be approved for a systemic disease.
Read more about this topic: Graft-versus-host Disease
Famous quotes containing the word disease:
“I prithee, daughter, do not make me mad.
I will not trouble thee, my child; farewell:
We’ll no more meet, no more see one another.
But yet thou art my flesh, my blood, my daughter—
Or rather a disease that’s in my flesh,
Which I must needs call mine.”
—William Shakespeare (1564–1616)